NCT07519395

A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)

BALANCE - A Two-part, 26-week, Randomized, Double-Blind, Dose-rAnging, pLAcebo-coNtrolled, Phase 2b Study to Evaluate the effiCacy and safEty of Camlipixant in Adults With IBS-D and IBS-M

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 420 (estimated)
• Sponsor: GlaxoSmithKline · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This study is designed to evaluate the efficacy and safety of camlipixant in adults with IBS-D and IBS-M. The study has two parts. After the first part, some participants will be randomly chosen again to either get a higher dose or stop the drug.

Conditions

• Irritable Bowel Syndrome

Interventions

Type	Name	Description
DRUG	Placebo	Placebo to be administered
DRUG	Camlipixant	Camlipixant to be administered

Timeline

• Start date: 2026-04-06
• Primary completion: 2027-03-05
• Completion: 2027-07-09
• First posted: 2026-04-09
• Last updated: 2026-04-09

Regulatory

• FDA-regulated drug study